Liver disease can be fatal, but whether it is depends almost entirely on how far it has progressed before it’s caught and treated. Early-stage liver disease is often reversible. Advanced cirrhosis, where scar tissue has replaced most functional liver tissue, kills roughly 1 in 5 people within a year. Globally, liver disease accounts for about 2 million deaths per year, or 1 out of every 25 deaths worldwide.
The critical distinction is between liver disease that’s still compensated (the liver is damaged but still functioning) and decompensated disease (the liver can no longer keep up). That single shift changes the picture from a manageable chronic condition to a potentially life-threatening one.
Why Stage Matters More Than Diagnosis
Liver disease is not one disease. It includes fatty liver, hepatitis, alcohol-related damage, autoimmune conditions, and genetic disorders. What they share is a common endpoint: if untreated, they can all progress to cirrhosis, where healthy liver tissue is replaced by permanent scar tissue. The liver has remarkable regenerative ability, so early-stage damage from any of these causes often heals if the underlying problem is addressed.
Once cirrhosis develops, the prognosis splits sharply depending on whether the liver is still compensating. In compensated cirrhosis, annual mortality is only 1 to 3.4%. Many people at this stage have no symptoms and don’t know they have cirrhosis. But when decompensation occurs, meaning the liver can no longer maintain its basic functions, one-year mortality jumps to 20 to 57%.
What Decompensation Looks Like
Decompensation announces itself through a set of recognizable complications. Fluid buildup in the abdomen (ascites) is the most common, and roughly 40 to 47% of people survive five years after it appears. Bleeding from enlarged veins in the esophagus or stomach is another hallmark, with five-year survival between 61 and 70%. The least common but most dangerous sign is hepatic encephalopathy, a state of confusion and cognitive decline caused by toxins the liver can no longer filter. Only 35 to 50% of people survive five years after encephalopathy develops.
A long-term study tracking 532 cirrhosis patients over 16 years found that 57% ultimately died of liver-related causes. The leading causes of death were liver failure (24%), gastrointestinal bleeding (14%), and a combination of both (13%). Notably, 22% died of cardiovascular disease and 9% of cancers unrelated to the liver, a reminder that cirrhosis doesn’t exist in isolation from the rest of the body.
How Doctors Estimate Survival
Two scoring systems help predict how dangerous a person’s liver disease has become. The Child-Pugh score groups patients into three classes based on lab values and symptoms. In a study of one-year outcomes, no Class A patients died, 20% of Class B patients died, and 55% of Class C patients died. If surgery is needed, those numbers are even starker: Class C patients face a 70 to 80% surgical mortality rate.
The MELD score, which runs on a numerical scale, is used to prioritize transplant candidates and gives a 90-day mortality estimate. The range is dramatic:
- Score below 9: 1.9% chance of death within 90 days
- Score 10 to 19: 6%
- Score 20 to 29: 19.6%
- Score 30 to 39: 52.6%
- Score above 40: 71.3%
If you or a family member has been given a MELD score, that number directly reflects how urgently treatment is needed.
Acute Liver Failure: A Different Timeline
Most liver disease progresses slowly over years or decades, but acute liver failure is a sudden collapse of liver function in someone who may have had a healthy liver days earlier. The most common cause is acetaminophen (Tylenol) overdose, though viral hepatitis and autoimmune flares can also trigger it. Without a transplant, acute liver failure is frequently fatal within days.
The cause of acute failure matters for outcomes. People with acetaminophen-related failure who receive a transplant have a 76% five-year survival rate. Those whose failure is caused by autoimmune hepatitis fare somewhat worse, with 83% surviving one year but only 62% at ten years. The best post-transplant outcomes come from Wilson’s disease, a genetic copper-storage disorder, with 95% surviving at one year and 86% at ten years.
When the Liver Begins Shutting Down
Certain late-stage complications signal that death may be weeks or months away without transplant. One of the most ominous is hepatorenal syndrome, where the failing liver drags the kidneys down with it. The more severe form, called type 1, carries a median survival of roughly 11 days without treatment, and only a 25% chance of surviving 30 days. The slower form, type 2, has a median survival of about six months. Patients who respond to treatment do significantly better, with median survival extending to about 29 months compared to 8 months for those who don’t respond.
When a combination of complications becomes refractory to treatment (ascites that won’t resolve, repeated bleeding episodes, persistent encephalopathy), clinicians consider the disease terminal with a life expectancy of six months or less.
Transplant Changes the Equation
For people with end-stage liver disease, transplantation is the only cure, and the outcomes are genuinely good. Among adults who receive a deceased-donor liver, 93.2% survive six months, 93.2% survive one year, and about 80% are alive at five years. Living-donor transplants perform even better, with 84% surviving at five years. For children, the numbers are more favorable still: over 90% survive five years.
The challenge is access. Among adults listed for transplant between 2017 and 2019, about 60% received a liver. Nine percent died while waiting, and another 15.6% were removed from the list because they became too sick for surgery. The wait itself carries real risk, with a pretransplant mortality rate of 12.3 deaths per 100 patient-years.
Fatty Liver Disease and Long-Term Risk
Non-alcoholic fatty liver disease is now the fastest-growing reason people end up on transplant waiting lists. Most people with simple fatty liver never develop serious complications. But the subset who develop inflammation (called NASH) face a meaningful risk of progression to cirrhosis. Among NASH cirrhosis patients listed for transplant, 29% died or deteriorated within three years of being listed, a rate comparable to alcohol-related cirrhosis.
The factors that increase the risk of dying on the waiting list include diabetes, poor physical function, encephalopathy, older age, and low blood protein levels. These are worth knowing because several of them, particularly diabetes management and physical conditioning, are modifiable even after a transplant listing.
The Window That Matters
The trajectory of liver disease is not a straight line toward death. It’s more like a staircase with long flat stretches and sudden drops. You can live for decades with compensated cirrhosis. You can have fatty liver for years without it ever progressing. But each decompensation event is a step down, and the steps get steeper. The gap between “manageable chronic illness” and “life-threatening organ failure” can close faster than people expect, which is why catching liver disease early, while the flat stretch is still long, changes everything about the outcome.